

Bcl-xL Is Necessary for Neurite Outgrowth in Hippocampal Neurons

Han-A Park, Pawel Licznanski, Kambiz N. Alavian, Marya Shanabrough, and Elizabeth A. Jonas

Abstract

Aims: B-cell lymphoma-extra large (Bcl-xL) protects survival in dividing cells and developing neurons, but was not known to regulate growth. Growth and synapse formation are indispensable for neuronal survival in development, inextricably linking these processes. We have previously shown that, during synaptic plasticity, Bcl-xL produces changes in synapse number, size, activity, and mitochondrial metabolism. In this study, we determine whether Bcl-xL is required for healthy neurite outgrowth and whether neurite outgrowth is necessary for survival in developing neurons in the presence or absence of stress. **Results:** Depletion of endogenous Bcl-xL impairs neurite outgrowth in hippocampal neurons followed by delayed cell death which is dependent on upregulation of death receptor 6 (DR6), a molecule that regulates axonal pruning. Under hypoxic conditions, Bcl-xL-depleted neurons demonstrate increased vulnerability to neuronal process loss and to death compared with hypoxic controls. Endogenous DR6 expression and upregulation during hypoxia are associated with worsened neurite damage; depletion of DR6 partially rescues neuronal process loss, placing DR6 downstream of the effects of Bcl-xL on neuronal process outgrowth and protection. *In vivo* ischemia produces early increases in DR6, suggesting a role for DR6 in brain injury. **Innovation:** We suggest that DR6 levels are usually suppressed by Bcl-xL; Bcl-xL depletion leads to upregulation of DR6, failure of neuronal outgrowth in non-stressed cells, and exacerbation of hypoxia-induced neuronal injury. **Conclusion:** Bcl-xL regulates neuronal outgrowth during development and protects neurites from hypoxic insult, as opposed by DR6. Factors that enhance neurite formation may protect neurons against hypoxic injury or neurodegenerative stimuli. *Antioxid. Redox Signal.* 22, 93–108.

Introduction

SPROUTING AND ELONGATION of neurites are critical for neuronal communication and survival. Formation of neuronal networks enables successful communication between neurons *via* specific synaptic connections. Failure of normal neuritogenesis leads to morphological changes and abnormalities in brain function (17, 19).

B-cell lymphoma-extra large (Bcl-xL) protein is a member of the Bcl2 protein family whose main function is to promote cell survival. Bcl-xL is abundantly expressed during development and in adult neurons and can translocate into mitochondria during death stimuli or neuronal activity (1, 6, 9). Bcl-xL prevents homo-oligomerization of pro-apoptotic family members such as Bax and Bak, directly inhibits

Innovation

Bcl-xL is a pro-survival protein that is located on the outer mitochondrial membrane and interacts with ATP synthase at the inner membrane. Previously, we reported that Bcl-xL conserves neuronal energy and facilitates synaptic function. We now show that Bcl-xL plays an important role in neurite outgrowth. We identify that DR6 is upregulated by Bcl-xL silencing and by hypoxia using *in vivo* ischemia and *in vitro* hypoxia models. This study suggests that Bcl-xL may regulate the formation of neuronal networks and that at least one and maybe more specific molecular pathways involving Bcl-xL and opposed by DR6 produce neuroprotection during hypoxia.

activators of Bax and Bak (25, 46, 48), and enhances cell metabolism by interacting with the ATP synthase (1, 6). In addition to its protective roles, Bcl-xL can play a pro-death role during neuronal ischemia by forming a cleaved pro-apoptotic moiety (2, 21, 38), although the anti-apoptotic and neuroprotective functions of Bcl-xL against various insults have been more widely reported (38, 42). In non-cell death-related roles, Bcl-xL enhances synapse formation and plasticity (13, 20, 27, 28) but whether it regulates neurite outgrowth is unknown.

Neurite outgrowth is known to be negatively regulated by death receptor 6 (DR6, TNFRSF21), a member of the tumor necrosis factor (TNF) receptor superfamily that contains an intracellular death domain. DR6 is widely expressed in the brain and is especially abundant in the hippocampus (18). Endogenous DR6 regulates developmental axonal pruning, but not somatic degradation, in a caspase 6 dependent manner, presumably through release of mitochondrial factors (36, 47, 53). In contrast to endogenous DR6, overexpressed DR6 induces cell (somatic) death, and this can be prevented by anti-apoptotic members of the Bcl2 family. Notably, the pro-apoptotic protein Bax is required for DR6-induced apoptosis (53) and for axonal pruning (36). Studies also show increased levels of DR6 in the brain of Down syndrome patients (18) that are predisposed to early Alzheimer's disease through early development of A β -containing plaques. In keeping with this observation, it has been recently reported that DR6 interacts with another β -amyloid precursor protein (APP) cleavage fragment (not A β) of the APP (36).

Since the full cell signaling pathways both upstream and downstream of Bcl-xL and DR6 are unknown, we studied the role of DR6 in normal neuritic outgrowth in the absence and presence of a death stimulus (hypoxia) in cells depleted of Bcl-xL by siRNA. We found that DR6 levels are increased when endogenous Bcl-xL is silenced, and this is correlated with a decline in neurite outgrowth over many days in culture, which is eventually followed by delayed cell (somatic) death. Depletion of DR6 reverses these changes. Neurite damage in Bcl-xL-depleted cells is accentuated compared with that of controls during hypoxia, dependent on DR6, suggesting that attenuation of neurite outgrowth and subsequent somatic death are under Bcl-xL and DR6 control, but that these changes are rapidly accelerated by a decline in oxygen availability.

Results

Synaptic connectivity and neural network formation are not only important for development and normal synaptic plasticity but may also be neuroprotective (12, 20). We previously reported that Bcl-xL depletion by siRNA or pharmacological inhibition of Bcl-xL caused a decrease in synaptic protein markers (28), and these structural changes were associated with changes in synaptic activity (27) but not with cell death.

Bcl-xL is depleted by siRNA

To test whether Bcl-xL expression can be targeted by RNAi gene silencing, we infected primary hippocampal neurons with recombinant adeno-associated virus (rAAV). Hippocampal cell lysate collected at 1, 2.5, or 4 weeks after rAAV transduction confirmed that Bcl-xL siRNA significantly decreased Bcl-xL expression in primary culture at 2.5 weeks of rAAV post-

infection, but not at 1 week (Fig. 1). In analyzing expressing cells, we found that fluorescence appeared strongly by 2.5 weeks and cells remained fluorescent (demonstrating continued successful expression of the rAAV construct) for approximately 5–6 weeks after infection. Since transduction rate is a critical factor in our study, we performed experiments when 70% or more of cells were expressing dsRED usually at 16–19 days after rAAV transduction. We note this time point as 2.5 weeks. Experiments performed at 8 and 29 days after rAAV transduction are noted as 1 and 4 weeks, respectively.

Bcl-xL depletion does not cause immediate cell death

Although Bcl-xL is thought to function as an anti-apoptotic molecule, its depletion did not appear to cause immediate cell death in non-stressed neurons. The activity of lactate dehydrogenase (LDH), a marker for cellular damage, was not significantly different between scrambled siRNA- and Bcl-xL siRNA-expressing neurons at 2.5 weeks after rAAV transduction (Fig. 2A). Although LDH is a widely accepted marker of cytotoxicity, it does not distinguish between necrosis and apoptosis. To test whether Bcl-xL siRNA induced apoptotic death in primary neurons, we stained neurons with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). As a positive control, to ensure the capability of TUNEL to detect fragmented DNA, we treated healthy, non-challenged neurons with nuclease to force DNA breakage before TUNEL staining. We observed that nuclease-exposed neurons express TUNEL-positive signals (Supplementary Fig. S1; Supplementary Data are available online at www.liebertpub.com/ars). There was no significant difference in TUNEL staining between scrambled- and Bcl-xL siRNA-expressing groups, suggesting that cell death as assayed by TUNEL staining was not increased in Bcl-xL-depleted cells (Fig. 2B, E). Cell survival, as assayed by Calcein retention, was also not found to be different when comparing scrambled- and Bcl-xL siRNA-expressing groups (Fig. 2C, D, F). Taken together, these data indicate that there is no increase in death in cells expressing Bcl-xL siRNA compared with controls at 2.5 weeks after viral transduction.

Bcl-xL depletion causes abnormal neurite outgrowth

We obtained images of hippocampal neurons at 1 week after rAAV transduction. Cells did not express rAAV-derived fluorescence at this time point, which indicated that siRNA expression was low (Fig. 3). Western blots also confirmed insufficient depletion of Bcl-xL at 1 week after rAAV transduction (Fig. 1A). Phase-contrast images of a group transduced for 1 week indicated that the number of neurites at the soma, the length of neurites, and the number of bifurcations within 100 μ m radius of the soma were not significantly different between the non-transduced, scrambled siRNA-, and Bcl-xL siRNA-expressing neurons (Fig. 3).

Although depletion of Bcl-xL did not influence neuronal viability at 2.5 weeks, we observed unexpected differences in neuronal morphology of Bcl-xL siRNA-expressing neurons compared with scrambled siRNA-transduced controls. Scrambled siRNA-transduced neurons grew neurites of $246.7 \pm 12.12 \mu$ m in length on average and some reached approximately 550 μ m at 2.5 weeks. However, Bcl-xL-depleted neuronal processes extended only on average $170.8 \pm 6.02 \mu$ m (Fig. 4B, D). Moreover, scrambled siRNA-transduced




FIG. 1. Depletion of Bcl-xL by siRNA in rAAV-transduced neurons. (A) Immunoblot of Bcl-xL protein amount from cell lysates isolated at 1, 2.5, or 4 weeks after rAAV transduction ($n=3$ samples in each group from three independent cultures). $*p < 0.05$ compared with corresponding scrambled siRNA-expressing group. ANOVA, Tukey's test. GAPDH serves as a protein loading control. (B) Immunocytochemistry of cultured hippocampal neurons at 2.5 weeks after rAAV transduction showing level of Bcl-xL expression. *Green*: Bcl-xL; *Red*: dsRED; *Blue*: DAPI-stained nuclei. The high power image of a single neuron is shown in the box. (C) Immunocytochemistry of cultured hippocampal neurons at 2.5 weeks after rAAV transduction showing colocalization of rAAV with neuronal markers. *Green*: NeuN; *Red*: dsRED; *Blue*: DAPI-stained nuclei. The high power image of a single neuron is shown in the box. Scale bar = 100 μm for (B) and (C). Bcl-xL, B-cell lymphoma-extra large; rAAV, recombinant adeno-associated virus. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

neurons formed more complex branching of axons and dendrites. Scrambled siRNA transduced neurons showed 7.45 ± 0.34 bifurcations on average within a 100 μm radius around the neuronal cell body. Bcl-xL siRNA-expressing neurons only showed 3.94 ± 0.18 branches on average within the same area (Fig. 4C, E). There was no significant difference in the degree of proximal neurite outgrowth at the soma (Fig. 4A), which suggests that until the day of introduction of the rAAV, both groups adhered to the subcellular matrix and extended at the same rate. Our results, therefore, show that Bcl-xL-depleted neurons have significantly decreased length and bifurcation of neurites, suggesting failure to form a normal neuronal network.

Very delayed cell death of Bcl-xL-silenced neurons follows slowing of neurite growth

We had previously shown and repeated in this study that Bcl-xL functional inhibition or gene depletion was not associated with neuronal death for approximately 2.5 weeks after rAAV introduction (Figs. 1 and 2) (28). To determine whether the changes in neurite morphology observed at 2.5 weeks were associated with delayed subsequent somatic demise after 2.5 weeks, we studied neurons at 4 weeks in culture. We found that Bcl-xL-depleted neurons began releasing significant amounts of LDH at 4 weeks after rAAV transduction (Fig. 5A) and many neuronal somata appeared

connected to short, thin, and fragmented neurites at this time; while control neuron neurites stretched a longer distance and had developed increased branching compared with 2.5 weeks (Fig. 5B–I). Therefore, we suggest that, after Bcl-xL depletion, cultured neurons over time fail to form or sustain neuronal networks and this is associated with delayed somatic death.

Depletion of DR6 partially recovers neurite growth arrest of Bcl-xL-depleted neurons

To determine factors that may be associated with neurite outgrowth arrest and/or delayed cell death, we tested candidates known to be implicated in neurite retraction/neurite plasticity or growth arrest (8, 47, 53). We determined that DR6 is a possible downstream target of Bcl-xL regulation. DR6 is reported to be necessary for normal axonal pruning in response to nerve growth factor withdrawal in spinal neurons (36). DR6 is widely expressed in neurons during pro-apoptotic states and is of interest given its role in neuronal growth and repair (35, 36, 44). In our preliminary screening, we measured DR6 expression in cultured hippocampal neurons depleted of Bcl-xL. We found an increased abundance of DR6 protein in Bcl-xL siRNA-expressing hippocampal neurons compared with scrambled siRNA-transduced controls, suggesting that DR6 expression may be suppressed by endogenous Bcl-xL.




FIG. 2. Depletion of Bcl-xL does not produce neuronal death at 2.5 weeks. Primary hippocampal neurons were transduced with rAAV for 2.5 weeks. (A) LDH release (number listed on each histogram refers to the number of plates). (B, E) TUNEL staining (number listed on each histogram refers to the number of plates for at least three independently isolated cultures, data represent 52–56 randomly generated micrographs from each group). *Green*: TUNEL; *Red*: dsRED; *Blue*: DAPI-stained nuclei (please note that preparation for TUNEL staining reduces dsRED signal in neurites). (C, D, F) Calcein retention (number listed on each histogram refers to the number of plates for at least three independently isolated cultures, data represent 48 randomly generated micrographs from each group). *Green*: Calcein; *Red*: dsRED; *Blue*: DAPI-stained nuclei. Two-tailed Student's *t*-test employed for statistical measurements. Scale bar for (E) and (F) = 50 μ m. LDH, lactate dehydrogenase; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

To test whether DR6 plays a role in Bcl-xL-mediated neuronal outgrowth, cells were coexpressed with DR6 siRNA along with Bcl-xL siRNA, or equal amounts of corresponding control viral constructs. GFP-tagged lenti-DR6 siRNA-expressing primary hippocampal neurons decreased DR6 protein level with $\sim 70\%$ knockdown efficiency (Fig. 6A). Depletion of DR6 did not enhance neurite outgrowth in scrambled siRNA-expressing neurons. However, DR6 depletion attenuated loss of neurite outgrowth in Bcl-xL siRNA-expressing neurons measured at 2.5 weeks of transduction. Although depletion of DR6 did not completely recover neuronal outgrowth in cells depleted of Bcl-xL, the length of neurites in the doubly depleted group was $\sim 35 \mu$ m longer, and the number of bifurcations was 1.3 higher than in Bcl-xL-depleted neurons, indicating that depletion of DR6 partially recovers neuronal outgrowth in the condition of Bcl-xL depletion (Fig. 6B–D). These findings support the notion that DR6 is one important downstream effector of Bcl-xL depletion during neurite outgrowth.

Cell death is enhanced by Bcl-xL depletion in vitro hypoxia

To elucidate the importance of intact neurite morphology in prevention of neurotoxic insult, we exposed primary cultures to hypoxia. To confirm hypoxic conditions, we measured oxygen

content in hypoxia-exposed cell culture medium (Supplementary Fig. S2). During preliminary screening, we observed that 1–3 h hypoxic exposure did not induce neurotoxicity, while 6 h hypoxia induced minor LDH release, and 72–96 h hypoxia caused massive irreversible hippocampal injury. Thus, we chose 24 h hypoxia to induce neurotoxicity in our culture system. In addition, we noted that 6 h hypoxia triggered caspase 6, caspase 3, and caspase 7 activation, indicating apoptotic signaling starting at time points earlier than 24 h. Depletion of Bcl-xL enhanced activation of caspases (Fig. 7A, B).

To study the vulnerability of Bcl-xL-depleted cells to hypoxia, hippocampal neurons were placed under hypoxic conditions for 24 h after 2.5 weeks of rAAV transduction. LDH release was significantly higher in Bcl-xL siRNA-expressing cells exposed to hypoxia compared with scrambled siRNA-transduced neurons exposed to hypoxia, indicating increased cytotoxicity after Bcl-xL depletion in the hypoxic cultures (Fig. 7C). We also observed that Bcl-xL siRNA-expressing neurons had significantly increased TUNEL staining after hypoxia (Fig. 7D, G), consistent with cell death. The viable cells were also much reduced. (Fig. 7E, F, H). Our viability and toxicity assays, therefore, showed that although depletion of Bcl-xL by itself did not induce neuronal death (Fig. 2), neurons depleted of Bcl-xL were more vulnerable than controls to hypoxic insult (Fig. 7) and displayed markers of cell death.




FIG. 3. Neuronal growth is not different at 1 week after rAAV transduction. Primary hippocampal neurons were transduced with rAAV for 1 week. Morphometric analysis was performed on phase-contrast images. **(A)** Number of neurites extending directly from soma (n = number of cells; three independently isolated cultures). **(B, D)** Length of neurites (n = number of cells; three independently isolated cultures). The low power image shows the full extent of neurites. **(C, E)** Number of bifurcations per cell (n = number of cells; three independently isolated cultures, *blue* dots on each image show bifurcations). The high power image shows bifurcations in the area of interest. ANOVA, Tukey's test. Scale bar for **(D)** = 100 μ m and **(E)** = 50 μ m. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

Bcl-xL depletion enhances neurite damage in hypoxic neurons

Neurite network damage is known to occur during hypoxic insults (49). To study this in our model, neurites of both scrambled- and Bcl-xL siRNA-expressing neurons were assayed at 24 h after hypoxic exposure. Controls were relatively protected compared with cells depleted of Bcl-xL during hypoxic insult. Scrambled siRNA-transduced neurons only suffered damage to small parts of the neuronal structure such as distal neurite tips. In contrast, the majority of Bcl-xL siRNA-expressing neurons completely lost their axons and neurites (Fig. 8A–E). We found discontinuous tracks of debris around broken somata and countless fluorescent positive fragments around intact somata, indicating severely damaged neurites in these hypoxic Bcl-xL-depleted neurons. Quantitatively, Bcl-xL siRNA-transduced hypoxic neurons displayed fewer somatic branches, greatly shortened neurite length, and many fewer bifurcations than scrambled siRNA-transduced hypoxic cells (Fig. 8A–E).

DR6 depletion protects against neurite damage during hypoxic insult

To understand any role of DR6 in neurite loss during hypoxic insult, hippocampal neurons were challenged with hypoxia for 24 h after 2.5 weeks of cotransduction, and cell morphology was analyzed in DR6 siRNA-expressing neurons (Fig. 9). We found significant protection from hypoxic insult in both scrambled and Bcl-xL-depleted groups. As evident in Figures 7 and 8, depletion of Bcl-xL increased vulnerability of neurons to hypoxic challenge. When Bcl-xL siRNA was coexpressed with DR6 siRNA, however, neurons partially retained neurite morphology, with strikingly improved neurite length and enhanced number of bifurcations compared with Bcl-xL siRNA alone.

Both Bcl-xL depletion and hypoxia increase DR6 levels

Although the earlier experiment supports a role for DR6 in hypoxic injury to neurites, it falls short of determining




FIG. 4. Depletion of Bcl-xL inhibits growth of neurites. Primary hippocampal neurons were transduced with rAAV for 2.5 weeks. Morphometric analysis was performed on the fluorescent images. (A) Number of neurites extending directly from the soma (n =number of cells; three independently isolated cultures). (B, D) Length of neurites (n =number of cells; three independently isolated cultures). The full extent of neurites is clearly seen in fluorescent images. (C, E) Number of bifurcations per cell (n =number of cells; three independently isolated cultures, blue dots show bifurcations). **** $p < 0.0001$, compared with scrambled siRNA-expressing neurons, two-tailed Student's t -test. Scale bar for (D)=100 μm and (E)=50 μm . To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

whether DR6 is a necessary downstream effector of Bcl-xL depletion during hypoxic insult. To further clarify this, we tested whether Bcl-xL depletion or hypoxia affected levels of DR6 expression. We found by immunoblotting that DR6 expression was markedly elevated in Bcl-xL-depleted normoxic neurons (Fig. 10A–C). In fact, depletion of Bcl-xL resulted in an ~ 2.9 -fold higher DR6 expression compared with scrambled siRNA controls. Hypoxia also produced DR6 protein upregulation to a level not significantly different from that produced by Bcl-xL depletion, suggesting that hypoxia could also induce increased DR6 (compare Fig. 10B, C), perhaps through pro-apoptotic cleaved Bcl-xL formation or Bcl-xL sequestration.

Both Bcl-xL depletion and hypoxia increase Bax activation

One role of Bcl-xL is to sequester BH3-containing molecules to prevent Bax activation (39). Bcl-xL depletion in neurons (Fig. 10D–F) increased formation of active Bax (~ 3.1 -fold higher than scrambled siRNA-transduced neurons), while other tested pro-apoptotic candidates (PUMA and NOXA) were unchanged (data for PUMA and NOXA

not shown). Hypoxia enhanced active Bax to about the same level as depletion of Bcl-xL alone, consistent with the notion that inhibition/sequestration of Bcl-xL during death stimuli activates Bax (14). We observed the highest level of active Bax formation in hypoxic Bcl-xL-depleted neurons, consistent with our findings of increased cell death and neurite loss in this group (Figs. 7 and 8) and consistent with the results for DR6 (Fig. 10A–C). The role of Bcl-xL in Bax activation (39) has been reported previously. We now suggest that there are parallels between Bax activation and DR6 upregulation. Furthermore, we suggest that not only does Bcl-xL depletion/sequestration during normoxia/hypoxia enhance activation of Bax and upregulation of DR6, but there may also be a role for other apoptotic mechanisms such as pro-apoptotic cleaved Bcl-xL formation (Fig. 10E, F).

DR6 levels are increased in vivo after transient global ischemia

To determine whether DR6 is important in neurotoxic injury *in vivo*, we studied transient global ischemia in rodents. We applied global ischemia in rodent brains for




FIG. 5. Prolonged depletion of Bcl-xL further inhibits neurite outgrowth and is associated with delayed neuronal death. Primary hippocampal neurons were transduced with rAAV for 4 weeks. Morphometric analysis was performed on the fluorescent images. (A) LDH release (n =number of plates). (B) Number of neurites extending directly from the soma (n =number of cells; three independently isolated cultures). (C, H) Length of neurites (n =number of cells; three independently isolated cultures). (D, I) Number of bifurcations per cell (n =number of cells; three independently isolated cultures, blue dots show bifurcations). *** p <0.001 and **** p <0.0001 compared with scrambled siRNA-expressing neurons. Two-tailed Student's t -test. (E) Number of neurites at three different time points (Figs. 3A, 4A and 5B as combined data). (F) Length of neurites at three different time points (Figs. 3B, 4B and 5C as combined data). (G) Number of bifurcations at three different time points (Figs. 3C, 4C and 5D as combined data). * p <0.05 compared with corresponding 1 week group, $^{\S}p$ <0.05 compared with corresponding 2.5 weeks group. ANOVA, Tukey's test. Scale bar for (H)=100 μ m and (I)=50 μ m. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

10 min using four-vessel occlusion (4VO). Ten minutes of occlusion does not produce edema or other complications, but results in very delayed apoptotic death in pyramidal neurons in the hippocampal CA1 and only sparsely in other areas (16, 37, 38, 43).

Animals that have undergone 4VO show little Fluoro-Jade positive signal at 24h, indicating a low level of neurodegeneration at that time point. However, rats express abundant Fluoro-Jade positivity in CA1 hippocampal neurons at 7 days after occlusion (Fig. 11A). We tested DR6 expression in ischemic brain tissue harvested at 24h after reperfusion when there is little Fluoro-Jade positivity. DR6 was upregulated at 24h after occlusion compared with sham. The early changes indicate that DR6 could be playing an early role in network

damage even before somatic death after ischemia *in vivo* (Fig. 11B, C).

Discussion

In this study, we show that Bcl-xL depletion by siRNA causes neurite growth arrest followed by delayed cell death. DR6 is necessary for full expression of the process of neurite growth arrest, as depletion of DR6 in Bcl-xL-depleted cells rescues neurite growth arrest. Once neurite arborization or extension is impaired, neurons become more vulnerable to an acute death stimulus. We show this in a model of brief hypoxia in hippocampal culture. Neurons that had been previously depleted of Bcl-xL fared much worse under hypoxic




FIG. 6. Depletion of DR6 partially rescues neuronal growth. Primary hippocampal neurons were coexpressed with lenti-copGFP or lenti-DR6 siRNA along with rAAV. After 2.5 weeks of transduction, images of cells were analyzed. **(A)** Immunoblot of DR6 protein level from cell lysate isolated at 2.5 weeks after viral transduction. **** $p < 0.0001$, compared with copGFP-expressing neurons, two-tailed Student's *t*-test. **(B, D)** Length of neurites (n = number of cells; three independently isolated cultures) **(C, D)** Number of bifurcations per cell (n = number of cells; three independently isolated cultures, blue dots show bifurcations). * $p < 0.05$ compared with corresponding copGFP-expressing group, § $p < 0.05$ compared with corresponding scrambled siRNA-expressing group. ANOVA, Tukey's test. Scale bar = 100 μm (50 μm for the last column). DR6, death receptor 6. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

conditions, demonstrating frank neuritic damage and loss as well as enhanced cell death. DR6 depletion protected from neurite loss during hypoxia, suggesting that Bcl-xL processing or sequestration during hypoxia stimulates the activities of DR6. Indeed, we discovered that DR6 was upregulated either after Bcl-xL depletion in normoxia and/or after hypoxia, suggesting its involvement to enhance neurite degeneration under these conditions.

The pro-apoptotic molecule Bax was also activated, suggesting a role for the mitochondrial apoptotic pathway in neurite degeneration. Previously, we have reported that Bcl-xL enhances synaptic activity and induces synapse formation *via* dynamin-related protein 1 (DRP1) (26), a large GTPase which is involved in dendritic outgrowth (10). Post-translational modification of DRP1 is reported to change mitochondrial function and regulate electron transport activity (32, 34). We also found that Bcl-xL enhances energy metabolism in hippocampal neurons (1, 6). The ability both to meet metabolic demand and to control energy production is tightly regulated in growing cells (51), and previous studies

have emphasized the importance of mitochondrial energy metabolism in neurite outgrowth (4, 26).

We suggest based on our data that failure to produce neurite outgrowth eventually leads to neuronal death, perhaps because unconnected synaptic endings signal apoptosis of the cell soma in a delayed fashion. We find that depletion of Bcl-xL produces shortened neurite length and a reduction in bifurcations which impairs normal neuronal network development over time. Neurites may be more susceptible than somata to altered energy metabolism given their role in neurotransmitter release and the sensitivity of this system to metabolic change (45). Impaired neurite growth is a noted pathological feature of many neurodegenerative diseases, including Alzheimer's and Parkinson's disease (7, 52), and an inverse relationship between neurite outgrowth and apoptosis has been previously reported (33, 50). We find here that failure of neurite growth may not only result from pathologic conditions in the nervous system but when stimulated *de novo*, may also serve as a potential trigger of cell death.




FIG. 7. Depletion of Bcl-xL aggravates hypoxia-induced neuronal death. Cultures were transduced for 2.5 weeks before 6 h of hypoxic exposure. Activity of caspase 6 (A), caspase 3 and 7 (B) was measured (n = number of wells). (C–F) Primary hippocampal neurons were transduced with rAAV for 2.5 weeks, and cells were exposed to hypoxia for 24 h. First two bars in each group represent the same data as in Figure 2. (C) LDH release (n = number of plates). (D) Number of TUNEL-positive cells (number listed on each histogram refers to the number of plates for at least three independently isolated cultures, data represent 48–56 micrographs). (E, F) Calcein retention (number listed on each histogram refers to the number of plates for at least three independently isolated cultures, data represent 48–60 micrographs). (G) TUNEL staining in hypoxic neurons. *Green*: TUNEL; *Red*: dsRED; *Blue*: DAPI-stained nuclei. (H) Calcein staining in hypoxic neurons. *Green*: Calcein; *Red*: dsRED; *Blue*: DAPI-stained nuclei. * p < 0.05 compared with corresponding normoxic group, $^{\#}p$ < 0.05 compared with corresponding scrambled siRNA-expressing group. ANOVA, Tukey's test. Scale bar for (G) and (H) = 50 μ m. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

We were particularly interested in the role of DR6 in this phenomenon, because DR6 is involved in axonal degradation and mitochondrially mediated apoptosis (36, 53). We found that neurons depleted of Bcl-xL showed a higher abundance of DR6 protein, which may contribute to the slowing of neurite outgrowth at 2.5 weeks of rAAV incubation. In addition, we noted DR6 upregulation during hypoxia. If, indeed, endogenous Bcl-xL suppresses DR6 expression, and hypoxia upregulates DR6, this predicts that endogenous Bcl-xL may suppress DR6 expression during normoxia or hypoxia. Under resting conditions, Bcl-xL and other anti-cell death molecules bind activating BH3-only molecules, preventing their interaction with, and activation of, Bax (23). After a death stimulus, however, inactivating BH3 molecules sequester Bcl-xL, releasing activating BH3 molecules to activate Bax (24). We have found that Bax is activated either by Bcl-xL depletion or during hypoxia, suggesting that Bcl-xL may become sequestered under hypoxic conditions. Therefore, Bcl-xL sequestration and Bax activation during hypoxia

could lead to upregulation of DR6 downstream of the hypoxic death stimulus (Fig. 12).

We also find that both hypoxia and Bcl-xL depletion increase activated caspase 6, placing Bcl-xL upstream of procaspase 6 proteolysis (Supplementary Fig. S3). Previously, the role of caspase 6 in axonal degeneration was reported (36, 47). Knocking down caspase 6 prevented axonal damage in these studies. In another work, overexpression of Bcl-xL inhibited cleavage of procaspase 6 under tetracycline-induced apoptotic conditions (53), which is consistent with our findings.

It is likely that Bcl-xL depletion mimics growth factor withdrawal (5, 31), possibly activating binding of endogenous ligands to DR6 (36). The possible scenario is that Bcl-xL depletion produces Bax translocation to mitochondria in neurites, initiating low-level early caspase 3 activation (30) that may be required for DR6 upregulation, enhancing neuritic degeneration *via* a positive feedback loop. Although our luminescence assay for caspase 3 levels is not positive in Bcl-xL-depleted cells, many reports indicate that caspase 3 activity




FIG. 8. Depletion of Bcl-xL increases loss of neurites after hypoxic exposure. Primary hippocampal neurons were transduced with rAAV for 2.5 weeks, and cells were exposed to hypoxia for 24 h. (A) Number of neurites arising from the soma (n = number of cells; three independently isolated cultures). (B, D) Neurite length (n = number of cells; three independently isolated cultures). (C, E) Number of bifurcations per cell (n = number of cells; three independently isolated cultures, blue dots show bifurcations). **** p < 0.0001, compared with scrambled siRNA-expressing neurons exposed to hypoxia, two-tailed Student's t -test. Scale bar for (D) = 100 μ m and (E) = 50 μ m. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

occurs soon after an acute stimulus for neurite degeneration (30), which is impossible to measure under our conditions of slow decline in Bcl-xL levels. Either DR6 or caspase 3 may be required for caspase 6 activation. Hypoxia also activates Bax and produces caspase activation, feeding into the same pathway. One role of Bcl-xL is to heterodimerize with Bax or BH3-only activator molecules, preventing Bax activation downstream of the DR6-ligand interaction (36). It is now clear from our study that Bcl-xL is also upstream of DR6 upregulation, as Bcl-xL depletion induces an upregulation in DR6 protein levels and depletion of DR6 protects against neuritic degeneration in Bcl-xL-depleted cells. It is, therefore, possible that Bcl-xL is upstream of a transcriptional or translational mechanism that suppresses DR6 protein production.

In addition to loss of full-length Bcl-xL, pro-apoptotic Bcl-xL proteolysis products may coordinate with Bax and release pro-apoptotic factors from mitochondria, further activating downstream caspases (38). In future studies, it will be important to elucidate whether Bcl-xL regulates DR6 *via* caspase activation, or whether Bcl-xL is involved in DR6 transcriptional/translational regulation in an independent pathway. Taken together, our findings indicate that Bcl-xL

mediates neuronal growth by regulating multiple signaling pathways, including one or more involving DR6, and it also specifically protects neuronal processes under hypoxic conditions. Therapeutic endeavors to activate Bcl-xL in the brain may protect neurons against hypoxia and neurodegeneration by enhancing neuritogenesis or neurite protection.

Materials and Methods

Primary cultures of rat hippocampal neurons

Primary rat hippocampal neurons were prepared from rat fetuses (Sprague-Dawley, day 18 of gestation; Harlan, Indianapolis, IN) as previously described (3, 22). After isolation of hippocampi from prenatal brains, neurons were dissociated and seeded (0.07×10^6 cells/35 mm plate) onto plates containing medium with 5% fetal bovine serum. After 2–4 h of incubation, cells were maintained in neurobasal medium supplemented with B-27, glutamine, and antibiotics (Invitrogen Gibco Life Technologies, Carlsbad, CA). Neurons were grown at 37°C in 5% CO₂ and 20% O₂ in a humidified incubator. Neurons were transduced with rAAV constructs (25,000 viral particles/ml) at 7 days *in vitro* (DIV),




FIG. 9. Depletion of DR6 rescues hypoxia-induced neurite loss. Primary hippocampal neurons were coexpressed with lenti-copGFP or lenti-DR6 siRNA along with rAAV. After 2.5 weeks of transduction, cells were exposed to hypoxia for 24 h. (A, C) Neurite length (n =number of cells; three independently isolated cultures). (B, C) Number of bifurcations per cell (n =number of cells; three independently isolated cultures, blue dots show bifurcations). * p <0.05 compared with corresponding copGFP-expressing group, $^{\S}p$ <0.05 compared with corresponding scrambled siRNA-expressing group. ANOVA, Tukey's test. Scale bar = 100 μ m (50 μ m for the last column). To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

and experiments were performed at 1, 2.5, or 4 weeks after rAAV introduction.

Construction and preparation of rAAV

The DNA fragments containing U6 promoter followed by shRNA sequence against rat Bcl-xL or scrambled siRNA were cloned into rAAV vector, in front of the ubiquitin promoter-DsRED expression cassette. The control siRNA was against EGFP sequence, thus lacking endogenous mRNA targets (11). rAAV2/1 viral stocks were produced as previously described (15). Briefly, human embryonic kidney (HEK293) cells were transfected with rAAV expression plasmid and pDp1 and pDp2 helper plasmids using Lipofectamine reagent (Invitrogen). Cell pellets were collected at 3 days post-transfection, lysed in three freeze-thaw cycles in a dry ice/ethanol bath. Next, collected lysates were filtered using 0.4 μ m gauge filters, and viruses were purified using HiTrap heparin HP affinity columns (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Viral titers were determined in rat hippocampal primary cultures. The scrambled siRNA sequences were as follows:

scrambled up: 5'-tttgaagctgacctgaagttctttt-3'
 scrambled down: 5'-cgaaaaagaactcagggtcagcttg-3'

The Bcl-xL shRNA sequences were:

Bcl-xL up: 5'-TTTggagtcagtttagcgatgctgGTGAAGCCA-CAGATGcgacatcgctaaactgactccTTTTT-3'

Bcl-xL down: 5'-CGAAAAaggagtcagtttagcgatgctgCAT-CTGTGGCTTCACcgacatcgctaaactgactc-3'

Neuronal growth analysis

Primary hippocampal neurons were transduced with rAAVs or a combination of lenti-DR6 shRNA or lenti-copGFP control (Santa Cruz, Dallas, TX) at DIV 7. Neuronal images were taken with a Zeiss Axiovert 200 microscope (Zeiss, Oberkochen, Germany) and processed using AxioVision 4.8 at the time point described in the relevant figure legends. All fluorescent images were taken consistently (RED, exposure time: 2000 ms; Green, exposure time: 2000 ms). Data were analyzed under the fluorescent channel, using the color-off setting. We found that fluorescent-based images were more sensitive to monitor neuronal growth compared with phase-contrast images (Supplementary Fig. S4). Although we obtained consistent data sets from phase-contrast images, these images failed to detect fine extensions of neurites. Therefore, all data in the main manuscript figures represent fluorescent images except the 1 week group.

Definitions. Number of neurites on soma: The number of neuritic extensions that directly connect to somata of hippocampal neurons.

Length of neurites: Largest distance from one end of the cell to the other end of the cell (neurite tip to neurite tip) measured using AxioVision 4.8.

Number of bifurcations: The number of branches of somatic neurites within 100 μ m radius of the soma. The center point of




FIG. 10. Depletion of Bcl-xL increases DR6 and activates Bax in hippocampal neurons in the absence and presence of hypoxic insult. (A) Immunoblots with the indicated antibodies. (B) Group data indicating band intensity normalized to GAPDH ($n=3$ independent cultures). (C) The same group data as in (B) now normalized to Bcl-xL. (D) Immunoblots with the indicated antibodies. (E) Group data indicating band intensity normalized to GAPDH ($n=3-5$ independent cultures). (F) The same group data as in (E) now normalized to Bcl-xL. * $p < 0.05$ compared with corresponding normoxic group, † $p < 0.05$ compared with corresponding scrambled siRNA-expressing group, § $p < 0.05$ compared with Bcl-xL-depleted normoxic group. ANOVA, Tukey's test.

a circle is placed on the center of the soma. Poorly visualized extensions or neurites shorter and $20 \mu\text{m}$ were excluded.

Induction and confirmation of hypoxia

Primary hippocampal neurons were challenged with hypoxia at 2.5 weeks after transduction. On the day of the experiment, hypoxic gas (5% CO_2 and 95% N_2) was flushed through a modular incubator chamber (Billups-Rothenberg, Inc., Del Mar, CA) for 5 min; then, the chamber was sealed and placed in an incubator maintained at 37°C . Cells were assayed at 24 h after hypoxic exposure as described in the corresponding figure legends. Composition of cell culture medium containing 25 mM glucose remained unchanged during hypoxic exposure. Ten to 20 ml sterile water was placed inside of the chamber to prevent evaporation of culture media. Oxygen content in the hypoxia-exposed cell culture medium was measured using a Clark-type electrode (Supplementary Fig. S2). Liquid-phase calibration was performed using an Oxygraph respirometer (Hansatech Instrument, King's Lynn, United Kingdom, kindly provided by Prof. Sabrina Diano) according to the manufacturer's protocol. Briefly, oxygen content in temperature-controlled, air-saturated, deionized water was analyzed and set as 100%. Zero-oxygen was obtained using sodium hydrosulfite ($\text{Na}_2\text{S}_2\text{O}_4$). One milliliter of either hypoxic or normoxic cell culture media was added into the chamber. Oxygen concentration was recorded at ten times per second using Oxygraph software at 37°C from three or four independently prepared plates and

normalized to the value for aerated water generated by the oxygen calibration.

Immunoblots

After protein extraction, protein concentration was determined using BCA protein reagents (Thermo Scientific, Rockford, IL). Samples (30–120 μg of protein/lane) were separated on a 4%–12% sodium dodecyl sulfate-polyacrylamide gel (Bio-Rad, Hercules, CA) and probed with anti-Bcl-xL (1:1000 dilution; Cell Signaling Technology, Danvers, MA), anti-caspase 6 (1:500 dilution; Cell Signaling Technology), anti-DR6 (1:500 dilution; NOVUS Biological, Littleton, CO), and anti-active bax (1:300; Enzo Life Science, Farmingdale, NY). To evaluate loading efficiency, membranes were probed with anti-GAPDH antibody (Sigma-Aldrich, St. Louis, MO). We confirmed that secondary antibodies do not produce false positive chemiluminescence signals (not shown). Images were analyzed using ImageJ software.

Immunocytochemistry

Primary hippocampal neurons fixed in 10% buffered formalin were blocked in 10% goat serum for 1 h, then incubated with anti-NeuN (1:100 dilution; Millipore, Billerica, MA), anti-Bcl-xL (1:100), anti-dsRED (1:100; Santa Cruz Biotechnology, Dallas, TX), and anti-RFP (1:100; Abcam, Cambridge, United Kingdom) overnight at 4°C . Cells were washed and incubated with Alexa-fluor 488 antibody or Alexa-568 antibody (1:200 dilution; Invitrogen, Molecular




FIG. 11. Global ischemia increases DR6 expression in CA1 hippocampal neurons. (A) Fluoro-Jade positive CA1 hippocampal neurons at 24 h or 7 days after 4VO-induced ischemia *in vivo*. (B) DR6-positive neurons per 300 μm length of the medial sector of the CA1 pyramidal cell layer in hippocampal slice (n = number of slices, five rats for 24 h sham; seven rats for 24 h ischemia). $*p < 0.05$ compared with sham-operated animals; two-tailed Student's *t*-test. (C) DR6- and NeuN-positive cells within slices from hippocampal CA1 region at 24 h after sham or 4VO-induced ischemia *in vivo* (Red: anti-DR6 antibody; Green: anti-NeuN antibody; Blue: DAPI-stained nuclei). The fluorescent positive cells were counted in a box (100 μm \times 300 μm) centered on the CA1 region. Scale bar for (A) and (C) = 100 μm . 4VO, four-vessel occlusion. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

Probes, Carlsbad, CA) for 1 h at room temperature and mounted on glass slides. Images were taken with a Zeiss Axiovert 200 microscope (Zeiss) and processed using AxioVision 4.8.

Viability assay

LDH assay. The viability of primary hippocampal neurons was assayed by measuring leakage of LDH using an *in vitro* toxicology assay kit (Sigma-Aldrich) as previously described (40, 41). Briefly, the culture media were collected from individual plates after treatment of neurons as described in the relevant figure legends; then, cells were lysed and collected separately. LDH assay mixture was made according to the manufacturer's protocol and added to each

sample. After 20 min of incubation, the reaction was terminated by adding 1N HCl. LDH activity was spectrophotometrically measured with a VICTOR³ multilabel reader (PerkinElmer, Waltham, MA) with absorbance set at 490 nm.

TUNEL assay. After treatment of neurons as described in the corresponding figure legends, cells were fixed in 10% buffered formalin. Quantification of DNA fragmentation was measured using an *in situ* apoptosis detection kit according to the manufacturer's protocol (Trevigen, Gaithersburg, MD). Terminal deoxynucleotidyl transferase incorporated nucleotide was labeled with strep-fluorescein, and 1 $\mu\text{g}/\text{ml}$ DAPI (Invitrogen) was used for nuclear counterstaining. All data were analyzed within dsRED-positive neurons, and dsRED-




FIG. 12. Model of Bcl-xL regulation of neurite degeneration. Death stimuli, including hypoxia or growth factor withdrawal, activate a ligand interaction with DR6 [1]. This interaction results in Bcl-xL sequestration [2] and Bax activation and oligomerization [3], causing permeabilization of mitochondria and downstream activation of caspases. In this model, either caspase activation or Bcl-xL sequestration/depletion leads to increased DR6 expression [4], representing a positive feedback loop for further neuritic damage. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars

negative cells were neither collected nor analyzed in this study. To obtain data from randomly collected images, we drew a square at the bottom of the glass or plate, and imaged an entire field of magnification just inside each corner of the square, leaving out the lines of the square so that the lines do not appear in the micrograph. Four corners together equal 0.2 mm^2 at $32\times$ magnification.

Calcein-AM. Calcein-AM is a neutral, hydrophobic, non-fluorescent, cell permeable compound that is a substrate for intracellular esterases and is hydrolyzed to membrane-impermeable, hydrophilic, and fluorescent Calcein in viable cells. After treatment of neurons as described in the corresponding figure legends, 25 nM Calcein-AM (Invitrogen) and $1 \mu\text{g/ml}$ DAPI were added to the culture medium for 30 min. Images were taken using a Zeiss Axiovert 200 microscope and analyzed using AxioVision 4.8. All data were randomly collected and analyzed within dsRED-positive neurons. dsRED-negative cells were neither collected nor analyzed in this study.

Caspase assay. After treatment of neurons as described in the corresponding figure legends, caspase activity was measured using Caspase Glo 6 assay kit and Caspase-Glo 3/7 assay kit (Promega, Madison, WI) based on the manufacturer's protocol. Briefly, plates were washed with sterile phosphate-buffered saline (PBS), and incubated with substrates (Ac-VEID-pNA or Ac-DEVD-pNA) for 30 min. Active caspases cleave luminogenic substrate and produce bioluminescence. Caspase-induced luminescence was measured with a VICTOR³ multilabel reader (PerkinElmer).

Four-vessel occlusion

Transient global ischemia was induced in 6–7 week-old male Sprague–Dawley rats as previously described (38, 43). Briefly, animals were anesthetized by isoflurane; then, left and right vertebral arteries were permanently occluded by

electrocauterization on the day before occlusion. After 24 h, both common carotid arteries were occluded with aneurysm clips and reperfused after 10 min. Animals were placed in their home cages, and sacrificed at 24 h or 7 days after 4VO. This surgical protocol enables oxygen glucose deprivation in the forebrain, but typically results in neurodegeneration in pyramidal neurons in the hippocampal CA1 and only sparsely in other areas of the brain. Animals suffering from complications (*e.g.*, pain, bleeding, or death) during or after 4VO were excluded. Sham animals were subjected to the identical procedure, minus carotid artery occlusion. Rats were maintained in a temperature- and light-controlled environment. All protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University, New Haven, CT.

Histology

Animals were euthanized and fixed by transcardial perfusion with ice-cold 4% paraformaldehyde (wt/vol) 0.1 M PBS, pH 7.4. Brains were removed and immersed in fixative. Coronal sections ($20 \mu\text{m}$) were cut and stained with 0.0001% Fluoro-Jade[®]C, anti-NeuN (1:100; Millipore), and anti-DR6 (1:100; Santa Cruz Biotechnology). Images were taken using a Zeiss Axiovert 200 microscope and analyzed by using AxioVision 4.8.

Statistical analysis

Data are reported as mean \pm SEM of at least three independently conducted experiments. Difference in means was tested using one-way ANOVA with Tukey's test or two-tailed Student's *t*-test. $p < 0.05$ was considered statistically significant. *p* values are provided in figure legends.

Acknowledgments

The authors appreciate very much the help and guidance they received from Dr. Naoki Kaneko and Dr. Suzanne Zukin of Albert Einstein College of Medicine in preparation for performing the *in vivo* studies.

Author Disclosure Statement

No competing financial interests exist.

References

- Alavian KN, Li H, Collis L, Bonanni L, Zeng L, Sacchetti S, Lazrove E, Nabili P, Flaherty B, Graham M, Chen Y, Messerli SM, Mariggio MA, Rahner C, McNay E, Shore GC, Smith PJ, Hardwick JM, and Jonas EA. Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial FIFO ATP synthase. *Nat Cell Biol* 13: 1224–1233, 2011.
- Basanez G, Zhang J, Chau BN, Maksaev GI, Frolov VA, Brandt TA, Burch J, Hardwick JM, and Zimmerberg J. Proapoptotic cleavage products of Bcl-xL form cytochrome c-conducting pores in pure lipid membranes. *J Biol Chem* 276: 31083–31091, 2001.
- Beaudoin GM, 3rd, Lee SH, Singh D, Yuan Y, Ng YG, Reichardt LF, and Arikath J. Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex. *Nat Protoc* 7: 1741–1754, 2012.

4. Belliveau DJ, Bani-Yaghoob M, McGirr B, Naus CC, and Rushlow WJ. Enhanced neurite outgrowth in PC12 cells mediated by connexin hemichannels and ATP. *J Biol Chem* 281: 20920–20931, 2006.
5. Chang BS, Kelekar A, Harris MH, Harlan JE, Fesik SW, and Thompson CB. The BH3 domain of Bcl-x(S) is required for inhibition of the antiapoptotic function of Bcl-x(L). *Mol Cell Biol* 19: 6673–6681, 1999.
6. Chen YB, Aon MA, Hsu YT, Soane L, Teng X, McCaffery JM, Cheng WC, Qi B, Li H, Alavian KN, Dayhoff-Brannigan M, Zou S, Pineda FJ, O'Rourke B, Ko YH, Pedersen PL, Kaczmarek LK, Jonas EA, and Hardwick JM. Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential. *J Cell Biol* 195: 263–276, 2011.
7. Crews L, Patrick C, Adame A, Rockenstein E, and Masliah E. Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. *Cell Death Dis* 2: e120, 2011.
8. Cusack CL, Swahari V, Hampton Henley W, Michael Ramsey J, and Deshmukh M. Distinct pathways mediate axon degeneration during apoptosis and axon-specific pruning. *Nat Commun* 4: 1876, 2013.
9. Cuttle L, Zhang XJ, Endre ZH, Winterford C, and Gobe GC. Bcl-X(L) translocation in renal tubular epithelial cells *in vitro* protects distal cells from oxidative stress. *Kidney Int* 59: 1779–1788, 2001.
10. Dickey AS and Strack S. PKA/AKAP1 and PP2A/Bbeta2 regulate neuronal morphogenesis via Drp1 phosphorylation and mitochondrial bioenergetics. *J Neurosci* 31: 15716–15726, 2011.
11. Dittgen T, Nimmerjahn A, Komai S, Licznerski P, Waters J, Margrie TW, Helmchen F, Denk W, Brecht M, and Osten P. Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring *in vivo*. *Proc Natl Acad Sci U S A* 101: 18206–18211, 2004.
12. Dorszewska J. Cell biology of normal brain aging: synaptic plasticity-cell death. *Aging Clin Exp Res* 25: 25–34, 2013.
13. Gal A, Pentelenyi K, Remenyi V, Wappler EA, Safrany G, Skopal J, and Nagy Z. Bcl-2 or bcl-XL gene therapy increases neural plasticity proteins nestin and c-fos expression in PC12 cells. *Neurochem Int* 55: 349–353, 2009.
14. Galonek HL and Hardwick JM. Upgrading the BCL-2 network. *Nat Cell Biol* 8: 1317–1319, 2006.
15. Grimm D, Kay MA, and Kleinschmidt JA. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. *Mol Ther* 7: 839–850, 2003.
16. Hara A, Mori H, and Niwa M. Novel apoptotic evidence for delayed neuronal death in the hippocampal CA1 pyramidal cells after transient ischemia. *Stroke* 31: 236–238, 2000.
17. He C, Qu X, Cui L, Wang J, and Kang JX. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. *Proc Natl Acad Sci U S A* 106: 11370–11375, 2009.
18. Iyer A, van Scheppingen J, Anink J, Milenkovic I, Kovacs GG, and Aronica E. Developmental patterns of DR6 in normal human hippocampus and in Down syndrome. *J Neurodev Disord* 5: 10, 2013.
19. Jiao X, Chen H, Chen J, Herrup K, Firestein BL, and Kiledjian M. Modulation of neuritogenesis by a protein implicated in X-linked mental retardation. *J Neurosci* 29: 12419–12427, 2009.
20. Jonas E. BCL-xL regulates synaptic plasticity. *Mol Interv* 6: 208–222, 2006.
21. Jonas EA, Hickman JA, Chachar M, Polster BM, Brandt TA, Fannjiang Y, Ivanovska I, Basanez G, Kinnally KW, Zimmerberg J, Hardwick JM, and Kaczmarek LK. Proapoptotic N-truncated BCL-xL protein activates endogenous mitochondrial channels in living synaptic terminals. *Proc Natl Acad Sci U S A* 101: 13590–13595, 2004.
22. Kaech S and Banker G. Culturing hippocampal neurons. *Nat Protoc* 1: 2406–2415, 2006.
23. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ, and Cheng EH. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies [see comment]. *Nat Cell Biol* 8: 1348–1358, 2006.
24. Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, and Cheng EH. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. *Mol Cell* 36: 487–499, 2009.
25. Ku B, Liang C, Jung JU, and Oh BH. Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. *Cell Res* 21: 627–641, 2011.
26. Lakshmi S and Joshi PG. Activation of Src/kinase/phospholipase C/mitogen-activated protein kinase and induction of neurite expression by ATP, independent of nerve growth factor. *Neuroscience* 141: 179–189, 2006.
27. Li H, Alavian KN, Lazrove E, Mehta N, Jones A, Zhang P, Licznerski P, Graham M, Uo T, Guo J, Rahner C, Duman RS, Morrison RS, and Jonas EA. A Bcl-xL-Drp1 complex regulates synaptic vesicle membrane dynamics during endocytosis. *Nat Cell Biol* 15: 773–785, 2013.
28. Li H, Chen Y, Jones AF, Sanger RH, Collis LP, Flannery R, McNay EC, Yu T, Schwarzenbacher R, Bossy B, Bossy-Wetzel E, Bennett MV, Pypaert M, Hickman JA, Smith PJ, Hardwick JM, and Jonas EA. Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons. *Proc Natl Acad Sci U S A* 105: 2169–2174, 2008.
29. This reference has been deleted.
30. Li Z, Jo J, Jia JM, Lo SC, Whitcomb DJ, Jiao S, Cho K, and Sheng M. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. *Cell* 141: 859–871, 2010.
31. Lindenboim L, Schlipf S, Kaufmann T, Borner C, and Stein R. Bcl-x(S) induces an NGF-inhibitable cytochrome c release. *Exp Cell Res* 297: 392–403, 2004.
32. Liu W, Acin-Perez R, Goghman KD, Manfredi G, Lu B, and Li C. Pink1 regulates the oxidative phosphorylation machinery via mitochondrial fission. *Proc Natl Acad Sci U S A* 108: 12920–12924, 2011.
33. Ma Y, Li J, Chiu I, Wang Y, Sloane JA, Lu J, Kosaras B, Sidman RL, Volpe JJ, and Vartanian T. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. *J Cell Biol* 175: 209–215, 2006.
34. Merrill RA, Dagda RK, Dickey AS, Cribbs JT, Green SH, Usachev YM, and Strack S. Mechanism of neuroprotective mitochondrial remodeling by PKA/AKAP1. *PLoS Biol* 9: e1000612, 2011.
35. Mi S, Lee X, Hu Y, Ji B, Shao Z, Yang W, Huang G, Walus L, Rhodes K, Gong BJ, Miller RH, and Pepinsky RB. Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. *Nat Med* 17: 816–821, 2011.
36. Nikolaev A, McLaughlin T, O'Leary DD, and Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. *Nature* 457: 981–989, 2009.

37. Nitatori T, Sato N, Waguri S, Karasawa Y, Araki H, Shibani K, Kominami E, and Uchiyama Y. Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. *J Neurosci* 15: 1001–1011, 1995.
38. Ofengeim D, Chen YB, Miyawaki T, Li H, Sacchetti S, Flannery RJ, Alavian KN, Pontarelli F, Roelofs BA, Hickman JA, Hardwick JM, Zukin RS, and Jonas EA. N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death. *Nat Neurosci* 15: 574–580, 2012.
39. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncino M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, and Rosenberg SH. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 435: 677–681, 2005.
40. Park HA, Khanna S, Rink C, Gnyawali S, Roy S, and Sen CK. Glutathione disulfide induces neural cell death via a 12-lipoxygenase pathway. *Cell Death Differ* 16: 1167–1179, 2009.
41. Park HA, Kubicki N, Gnyawali S, Chan YC, Roy S, Khanna S, and Sen CK. Natural vitamin E alpha-tocotrienol protects against ischemic stroke by induction of multidrug resistance-associated protein 1. *Stroke* 42: 2308–2314, 2011.
42. Parsadanian AS, Cheng Y, Keller-Peck CR, Holtzman DM, and Snider WD. Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons. *J Neurosci* 18: 1009–1019, 1998.
43. Pulsinelli WA and Brierley JB. A new model of bilateral hemispheric ischemia in the unanesthetized rat. *Stroke* 10: 267–272, 1979.
44. Qiu CW, Sheng B, and Liu J. A new therapy for the reduction of axon and neuron loss and promotion of axon and oligodendrocyte regeneration through inhibition of death receptor 6 pathway after ischemic cerebral stroke. *Med Hypotheses* 79: 853–855, 2012.
45. Rangaraju V, Calloway N, and Ryan TA. Activity-driven local ATP synthesis is required for synaptic function. *Cell* 156: 825–835, 2014.
46. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, and Fesik SW. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. *Science* 275: 983–986, 1997.
47. Simon DJ, Weimer RM, McLaughlin T, Kallop D, Stanger K, Yang J, O'Leary DD, Hannoush RN, and Tessier-Lavigne M. A caspase cascade regulating developmental axon degeneration. *J Neurosci* 32: 17540–17553, 2012.
48. Soane L, Siegel ZT, Schuh RA, and Fiskum G. Postnatal developmental regulation of Bcl-2 family proteins in brain mitochondria. *J Neurosci Res* 86: 1267–1276, 2008.
49. Takano T, Tian GF, Peng W, Lou N, Lovatt D, Hansen AJ, Kasischke KA, and Nedergaard M. Cortical spreading depression causes and coincides with tissue hypoxia. *Nat Neurosci* 10: 754–762, 2007.
50. Turgeon VL, Lloyd ED, Wang S, Festoff BW, and Houenou LJ. Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. *J Neurosci* 18: 6882–6891, 1998.
51. Ward PS and Thompson CB. Signaling in control of cell growth and metabolism. *Cold Spring Harb Perspect Biol* 4: a006783, 2012.
52. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT, Ogholikhan S, Aigner R, Winkler J, Farrer MJ, and Gage FH. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. *Neurobiol Dis* 41: 706–716, 2011.
53. Zeng L, Li T, Xu DC, Liu J, Mao G, Cui MZ, Fu X, and Xu X. Death receptor 6 induces apoptosis not through type I or type II pathways, but via a unique mitochondria-dependent pathway by interacting with Bax protein. *J Biol Chem* 287: 29125–29133, 2012.

Address correspondence to:

Dr. Elizabeth A. Jonas

Section of Endocrinology

Department of Internal Medicine

Yale University

PO Box 208020

New Haven, CT 06520

E-mail: elizabeth.jonas@yale.edu

Date of first submission to ARS Central, August 2, 2013; date of final revised submission, April 28, 2014; date of acceptance, April 29, 2014.

Abbreviations Used

4VO = four-vessel occlusion
 APP = β -amyloid precursor protein
 Bcl-xL = B-cell lymphoma-extra large
 DIV = days *in vitro*
 DR6 = death receptor 6
 DRP1 = dynamin-related protein 1
 LDH = lactate dehydrogenase
 PBS = phosphate-buffered saline
 rAAV = recombinant adeno-associated virus
 TNF = tumor necrosis factor
 TUNEL = Terminal deoxynucleotidyl transferase
 dUTP nick end labeling